Headquartered in Biopole, Epalinges Fiscal year ends December NYSE: ADCT adctherapeutics.com
ADC Therapeutics SA is a commercial-stage biotechnology company focused on antibody drug conjugates (ADCs).
Its sole marketed product is ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC carrying a pyrrolobenzodiazepine (PBD) payload. ZYNLONTA has FDA accelerated approval and EU conditional approval for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Continued approval depends on confirmatory data. The company is pursuing broader use through:
- the Phase 3 LOTIS-5 trial (with rituximab)
- the Phase 1b LOTIS-7 trial (with glofitamab)
- investigator-initiated studies in marginal zone lymphoma, mantle cell lymphoma, Waldenström macroglobulinemia and follicular lymphoma
Revenue comes mainly from U.S. ZYNLONTA product sales, plus license revenues and royalties from partners. These include Tanabe Pharma in Japan, which has filed for approval there and sublicensed commercialization to Nippon Shinyaku.
The company has scaled back early research, including discontinued programs and completed IND-enabling work on a PSMA-targeting ADC, to concentrate on ZYNLONTA.
In October 2026 it completed a financial restructuring:
- an $86.6 million PIPE led by Bain Capital Life Sciences
- removal of a $150 million change-of-control payment from its HealthCare Royalty agreement
- reduction of its senior secured loan to $50 million
The company is also considering a redomiciliation to Delaware. Updated
Operating expenses fell 24% year over year to $36.07 million while ZYNLONTA volume pushed revenue up 32.2%, the fourth straight quarter ahead of consensus, and October's $86.6 million PIPE plus a $68.5 million debt paydown stretch the cash runway into 2029. The open question is the FDA's serious concerns on LOTIS-5, with full results due at ASH next month.
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Monday's top analyst upgrades and downgrades included Ally Financial, Arbor Realty Trust, Azek, Chesapeake Energy, C3.ai, Endeavor, First Solar, Kingsoft Cloud, Kite Realty, Medtronic and Opendoor Technologies.
Wednesday's top analyst upgrades and downgrades included Allstate, Ally Financial, Five9, General Electric, Host Hotels, Nucor, PayPal, Trade Desk and Zillow.
Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.
These are some of this Monday’s top analyst research summaries of upgrades and downgrades from Wall Street firms: ARM Holdings plc (NASDAQ: ARMH) Cut to Sell at Benchmark. ADC Telecommunications (NASDAQ: ADCT)…
The latest and M&A deal in the world of technology and communications came to ADC Telecommunications Inc. (NASDAQ: ADCT) this week, where Tyco Electronics, Ltd. (NYSE: TEL) is paying $12.75 per share…
These are some of this Wednesday’s top analyst calls with upgrades, downgrades, and initiations seen from Wall Street firms: ADC Telecommunications Inc. (NASDAQ: ADCT) Cut to Hold at Jefferies. Allstate Corp. (NYSE:…
There are many movers today, but a lack of the double-digit gainers and losers we have seen. The movers on news this Thursday for day traders and active traders are ADC Telecommunications…
These are this Monday morning’s top analyst upgrades, downgrades, and initiations seen in early Wall Street research notes: ADC Telecommunications Inc. (NASDAQ: ADCT) Raised to Neutral at JPMorgan. Cisco Systems, Inc. (NASDAQ:…
These are some of the top analyst downgrades we are seeing from Wall Street firms this Thursday morning with more than two hours to the open: ADC Telecommunications (ADCT) Cut to Underweight…
ADC Telecom (NASDAQ: ADCT) is trimming its fiscal revenue guidance and throwing out almost every other bit of key restructuring and financial data to offer some stability to the situation. The telecom…
Douglas A. McIntyre These are some of the top downgrades or negative analyst calls we are seeing this Wednesday morning in early pre-market hours: ADC Telecom (ADCT) Cut to Neutral at Baird; Cut to Market…
These aren’t all of the downgrades or negative analyst calls we have seen this Wednesday, but these are some of the impact analyst calls we are seeing: ADC Telecommunications (NASDAQ: ADCT) Cut…
These are ten of the analyst calls we are focusing on this Friday morning: ADC Telecom (NASDAQ: ADCT) raised to Overweight at JPMorgan. AnnTaylor (NYSE: ANN) raised to Outperform at FBR. Ashland…
These are some of the top analyst calls we are looking at this Wednesday morning: ADC Telecom (NASDAQ: ADCT) raised to Buy from Hold at Jefferies. Alexion Pharma (NASDAQ: ALXN) started as…
ADC Therapeutics SA is a commercial-stage biotechnology company focused on antibody drug conjugates (ADCs). Its sole marketed product is ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC carrying a pyrrolobenzodiazepine (PBD) payload.
The Wall Street consensus 12-month price target for ADCT is $3.33.
